Lateral Septal PACAP Signaling Modulates Stress and Anxiety in Rodent Models

Neuropeptide Signaling and the Neurobiology of Stress Coping

Anxiety and trauma-related disorders represent a significant global health burden, often characterized by maladaptive physiological responses to environmental stressors [1]. While traditional pharmacotherapy often targets monoamine systems, emerging research highlights the role of neuropeptides in fine-tuning the neural circuitry of emotion and fear processing [2]. Pituitary adenylate cyclase-activating polypeptide (PACAP), a highly conserved peptide, has been increasingly linked to the regulation of the hypothalamic-pituitary-adrenal axis and the development of post-traumatic stress disorder [3]. Specific pathways involving PACAP receptors are now known to mediate complex behaviors ranging from panic-like symptoms to social avoidance [4, 5]. A new study now offers fresh insights into how localized signaling of this peptide within the limbic system dictates the transition between active and passive stress-coping strategies.

Stress-Induced Alterations in Regional Neuropeptide Expression

To understand the molecular response to environmental pressure, the researchers utilized quantitative polymerase chain reaction (a laboratory technique used to measure the amount of specific genetic material) to evaluate the expression of pituitary adenylate cyclase-activating polypeptide (PACAP) across various limbic regions. The study found that acute physiological challenges trigger a widespread increase in neuropeptide activity. Specifically, quantitative PCR showed that forced swim stress increases PACAP mRNA expression in the lateral septum, a key subcortical structure involved in the regulation of emotional behavior and the integration of sensory information with motor responses. This upregulation was not limited to the septum; the data demonstrated that forced swim stress increases PACAP mRNA expression in the bed nucleus of the stria terminalis, an area that serves as a critical relay in the extended amygdala for stress integration and sustained anxiety states. Additionally, the researchers observed that forced swim stress increases PACAP mRNA expression in the basolateral amygdala, a region central to the processing of fear and the formation of emotional memories. These findings suggest that acute stress rapidly recruits PACAP signaling across a distributed network of limbic structures to coordinate a systemic response.

The neurobiological profile shifted significantly when the subjects were subjected to prolonged, unpredictable stressors rather than a single acute event. While acute stress caused a broad elevation of the neuropeptide, chronic variable mild stress reduced PACAP expression in the lateral septum only, leaving other limbic areas unaffected. This localized downregulation suggests that the lateral septum may undergo unique molecular adaptations during the transition from acute arousal to chronic stress states. For the clinician, these findings highlight how the duration and nature of a stressor can differentially impact the molecular landscape of the brain, potentially influencing the shift from adaptive coping to the maladaptive patterns seen in chronic anxiety and trauma-related disorders. The specificity of the septal response to chronic stress suggests this region may be particularly vulnerable to the long-term effects of environmental pressure, potentially serving as a biomarker for the transition to chronic psychiatric pathology.

Neuroendocrine Activation and Behavioral Coping Strategies

To investigate the functional consequences of increased neuropeptide activity, the researchers performed local administration of PACAP38 (the 38-amino acid isoform of the peptide) directly into the lateral septum. This intervention significantly influenced the hypothalamic-pituitary-adrenal axis, which is the primary hormonal system governing the physiological response to stress. The study found that local administration of PACAP38 into the lateral septum potentiated stress-induced adrenocorticotropic hormone (ACTH) release, the pituitary hormone responsible for stimulating the adrenal cortex to produce glucocorticoids. For the clinician, this suggests that elevated septal signaling of this neuropeptide may drive a hyper-responsive neuroendocrine state, potentially contributing to the systemic hormonal dysregulation and hypercortisolemia often observed in patients with acute stress disorders.

Beyond hormonal changes, the researchers examined how this signaling pathway alters behavioral responses to environmental challenges using a forced swim challenge (a standardized behavioral test used to assess stress-coping strategies by measuring the ratio of active escape attempts to immobility). The results demonstrated a distinct shift in how the subjects managed the stressor. Specifically, local administration of PACAP38 into the lateral septum increased passive coping behavior, specifically floating, a state characterized by immobility and a lack of effort to escape. Simultaneously, the data showed that local administration of PACAP38 into the lateral septum reduced active coping behavior, specifically struggling, which represents the attempt to navigate or overcome the stressful situation. This shift from active to passive strategies is a hallmark of behavioral despair.

These behavioral findings are clinically relevant as they mirror the transition toward learned helplessness, a psychological state where an individual perceives a lack of control over stressful events, often seen in major depressive disorder and post-traumatic stress disorder. The increase in floating and the corresponding decrease in struggling indicate that enhanced signaling in the lateral septum may promote motivational deficits and a transition to depressive-like states. By identifying the lateral septum as a site where neuropeptide signaling modulates the choice between active and passive coping, this research provides a neurobiological framework for understanding why certain patients may adopt maladaptive, passive behaviors when faced with severe environmental pressure. This suggests that targeting the lateral septum could potentially help shift patients from a state of behavioral paralysis toward more active, adaptive engagement with their environment.

Anxiogenic Effects and Motivational Deficits

The researchers further characterized the behavioral impact of this neuropeptide by evaluating how its activity in the lateral septum influences anxiety and self-care behaviors. In the elevated plus-maze, a standardized behavioral test used to measure anxiety levels by assessing the willingness to explore open versus enclosed spaces, intraseptal PACAP38 administration significantly increased anxiety-like behavior. This finding suggests that acute elevations of pituitary-adenylate-cyclase-activating-polypeptide in this specific limbic region can drive a state of heightened avoidance and apprehension. Beyond generalized anxiety, the study also identified a negative impact on motivational states. Specifically, intraseptal PACAP38 administration reduced grooming behavior in the sucrose splash test, an assessment of self-care and motivational states where a sticky solution is applied to the subject to trigger a grooming response. For the clinician, this reduction in self-directed maintenance behavior serves as a behavioral correlate for the diminished motivation and neglect of self-care often observed in patients suffering from severe depressive or anxiety disorders.

To determine if endogenous signaling of this system contributes to baseline anxiety levels, the study utilized a pharmacological blockade of the receptor. The researchers found that intra-lateral septum administration of the PACAP receptor antagonist PACAP(6-38) produced a robust anxiolytic (anxiety-reducing) phenotype in the elevated plus-maze. This observation is clinically significant because it demonstrates that blocking the naturally occurring activity of this neuropeptide in the lateral septum can effectively lower anxiety levels. By showing that an antagonist can reverse or prevent these behavioral deficits, the data identify the PACAP/PAC1 receptor system as a potential target for future neuromodulatory interventions. These findings collectively suggest that while excessive signaling in the lateral septum promotes a state of high anxiety and low motivation, pharmacological inhibition of this pathway may offer a therapeutic avenue for stabilizing emotional and motivational processes in stress-related psychiatric conditions. This provides a potential pharmacological target for patients who do not respond to traditional selective serotonin reuptake inhibitors.

Clinical Relevance for Trauma and Depressive Disorders

The clinical implications of these findings center on the understanding that severe and/or repeated stress exposure can lead to a number of maladaptive physiological and behavioral changes that contribute to psychiatric illnesses. For the practicing clinician, identifying the biological drivers of these changes is essential for developing targeted therapies. This study confirms that the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) plays an important role in stress-related psychopathologies relevant to depression and trauma-related disorders such as PTSD. By focusing on the lateral septum (LS), a limbic structure where PACAP and its cognate PAC1 receptors are abundantly expressed, the researchers have localized a key node in the brain's stress-processing architecture. This region serves as a critical interface between emotional processing and the physiological stress response, making it a primary site of interest for understanding how acute and chronic stressors translate into clinical symptoms.

The data provide the first direct evidence that PACAP/PAC1 receptor signaling in the lateral septum (LS) modulates emotional and motivational processes in response to stress, identifying this system as a potential target for neuromodulatory interventions in stress-related psychiatric disorders. Because the study demonstrated that local administration of PACAP38 into the LS potentiates the release of adrenocorticotropic hormone (ACTH) and shifts behavior toward passive coping, it offers a mechanistic explanation for the neuroendocrine dysregulation and lethargy often seen in patients with treatment-resistant depression or PTSD. Furthermore, the observation that a receptor antagonist, PACAP(6-38), can produce a robust anxiolytic phenotype suggests that pharmacological modulation of this specific limbic circuit could eventually provide a way to stabilize patients who exhibit maladaptive stress responses. For physicians managing complex trauma and mood disorders, these findings highlight the PACAP/PAC1 system in the lateral septum as a discrete neurochemical pathway that may be manipulated to restore healthy emotional and motivational functioning, potentially offering a more localized approach to treatment than systemic medications.

References

1. Satao KS, Doshi GM. Anxiety and the brain: Neuropeptides as emerging factors.. Pharmacology, biochemistry, and behavior. 2024. doi:10.1016/j.pbb.2024.173878

2. Riser M, Norrholm SD. Pituitary Adenylate Cyclase Activating Peptide and Post-traumatic Stress Disorder: From Bench to Bedside.. Frontiers in psychiatry. 2022. doi:10.3389/fpsyt.2022.861606

3. Ebner K, Fontebasso V, Ferro F, Singewald N, Hannibal J. PACAP regulates neuroendocrine and behavioral stress responses via CRF-containing neurons of the rat hypothalamic paraventricular nucleus. Neuropsychopharmacology. 2024. doi:10.1038/s41386-024-02016-9

4. Kang SJ, Kim J, Kim D, Roberts BZ, Han S. A pontomesencephalic PACAPergic pathway underlying panic-like behavioral and somatic symptoms in mice.. Nature neuroscience. 2024. doi:10.1038/s41593-023-01504-3

5. Boucher MN, Aktar M, Braas KM, May V, Hammack SE. Activation of Lateral Parabrachial Nucleus (LPBn) PACAP-Expressing Projection Neurons to the Bed Nucleus of the Stria Terminalis (BNST) Enhances Anxiety-like Behavior.. Journal of molecular neuroscience : MN. 2022. doi:10.1007/s12031-021-01946-z